Novo Nordisk's New CEO Has a Plan. Wall Street Isn't Sure It Believes Him.

The other half of the playbook is M&A. Doustdar has given his business development team what amounts to a blank check, telling them Novo "can go very big, very big in buying something" to fill pipeline gaps. He's quick to add a caveat: "It is not about the size of the deal as much as it's about the right deal." But the intent is clear. Novo is shopping aggressively.

They've already been busy. The $4.7 billion acquisition of Akero Therapeutics brought in efruxifermin, a Phase 3 FGF21 drug for MASH (the liver disease formerly known as NASH, which is tightly linked to obesity). A $2.1 billion deal for Omeros added rare blood disorder assets. And a partnership with United BioPharma, worth around $2 billion, secured rights to triple-acting gut hormone peptides that go beyond traditional GLP-1 biology.

Beyond the Blockbuster: What's Actually in the Pipeline

The most interesting part of Doustdar's strategy isn't what Novo has today; it's what's coming next.

Amycretin, a dual GLP-1 and amylin receptor agonist, is planned to enter Phase 3 trials in Q1 2026. Analysts view it as the potential successor to Wegovy by roughly 2028, offering deeper weight loss through a different biological mechanism. Oral semaglutide for obesity just received a positive recommendation from the EU's medicines committee, making it the first GLP-1 pill approved for weight loss in Europe, with a full U.S. rollout already underway.

Novo is also pushing into rare disease territory that has nothing to do with GLP-1: etavopivat for sickle cell disease showed positive Phase 3 results, and coramitug targets a rare cardiac condition called ATTR amyloidosis.

Then there's a higher dose of injectable Wegovy, designed to deliver about 20% weight loss, explicitly engineered to "close the gap with our competitor," as Doustdar put it. No subtlety there.

Wall Street's Verdict: Show Me

Investors are listening politely and keeping their wallets closed. Novo's 2026 guidance calls for sales and operating profit to drop 5 to 13%, a number that landed well below what analysts expected. JPMorgan and Bank of America both flagged roughly 8% downside to their previous sales estimates. Deutsche Bank's Emmanuel Papadakis captured the mood when he said "enough has occurred in the past week to occupy a few volumes" while cutting his price target.

Only about 17% of covering analysts currently rate Novo a "buy." The majority sit at hold or neutral, waiting for proof that Doustdar's plans translate into results.

The credibility problem is real. Novo issued multiple profit warnings in 2025, underestimated competition from compounded semaglutide knockoffs, and misjudged the self-pay obesity market. One bad forecast is a mistake; two starts looking like a pattern. Shares dropped around 17-18% after one particularly grim guidance update.

Barclays floated an interesting theory: this might be a "kitchen sink" guide, where management deliberately sets the bar low so they can beat it later. The problem? Novo tried that argument last year too, and results still disappointed.

The Bigger Picture: A Two-Horse Race (For Now)

Zoom out and the obesity drug market looks like a very expensive tennis match. Lilly leads with roughly 55-60% market share in obesity GLP-1s. Novo holds the rest. Together, they control essentially all commercial revenue in the space.

But the stands are filling up. Amgen's MariTide is in late-stage trials. Viking Therapeutics' VK2735, a dual GLP-1/GIP agonist, is in Phase 3. Roche (via its Carmot acquisition) is pushing an oral GLP-1 candidate through Phase 2. None of them will have meaningful obesity sales in 2026, but by 2028 or 2030, the duopoly could crack.

Even losing share in a market that enormous can still mean growth. The question is whether Novo grows fast enough to satisfy investors accustomed to the rocket-ship trajectory of 2022-2024.

Can the Copy Room Kid Pull It Off?

Doustdar's journey from office clerk to CEO is a genuinely great story. He spent 33 years at Novo, running operations across the Middle East, Southeast Asia, and eventually all global markets outside the U.S., where international sales more than doubled under his watch.

But running the whole company during its most competitive period ever is a different challenge. He needs CagriSema approved (expected late 2026 or early 2027) despite its head-to-head loss. He needs amycretin to deliver in Phase 3. He needs M&A to fill gaps without overpaying. And he needs to convince a skeptical Wall Street that 2026 is a reset year, not the start of a decline.

Doustdar has told investors to "wait and see," hinting at pipeline developments not yet disclosed. He's asked them to judge "quarter by quarter." That's the language of a CEO who believes he's holding better cards than the market thinks.

Whether he's right will define the next chapter of the obesity drug wars.

The FDA Just Declared War on Cheap Ozempic

The FDA just launched its largest-ever coordinated crackdown on compounding pharmacies selling cheap versions of Ozempic and Wegovy, explicitly targeting Hims & Hers in the process. A multibillion-dollar grey market is being dismantled, and the fallout is reshaping telehealth, Big Pharma, and patient access to the most popular drugs in America.